Press Releases

August 11, 2026

USPTO Issues Foundational Patent for Leptin Replacement in Anorexia Nervosa, Exclusively Licensed to Zula Therapeutics

Zula Therapeutics, Inc. today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,651,658, titled "Methods for Treating Anorexia Nervosa and Related Conditions by Administering a Leptin Receptor Agonist." Zula holds exclusive rights under its license with the University of Duisburg-Essen (UDE).

Media Resources